A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy is a phase 3 interventional study registered as NCT04873362 by Hoffmann-La Roche, with 1188 participants enrolled, started 2021-05-04 and due to reach its primary completion in 2027-03-31. Interventions recorded: Atezolizumab, Trastuzumab Emtansine, Placebo and Trastuzumab.
Similar pages
not linked directly; found by shared links- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Trastuzumab emtansine, Flatiron Health (Roche), Atezolizumab, Trastuzumab and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Flatiron Health (Roche), Trastuzumab and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Shares Flatiron Health (Roche), HER2-positive breast cancer and the tag pipeline.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab emtansine, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.